Hormonal
Obesity-related sub-acute chronic inflammation acts as a pathologic mediator for both type 2 diabetes and atherosclerotic cardiovascular disease, with inflammatory markers like CRP predicting risk independently of weight.
If you have obesity or type 2 diabetes, your body's chronic low-grade inflammation is likely driving your risk for heart disease and worsening insulin resistance. While weight loss reduces this inflammation, specific anti-inflammatory strategies (like certain diabetes or cardiovascular drugs) may offer additional protection. Discuss with your doctor whether your current regimen addresses inflammatory risk, not just blood sugar or weight.
Obesity-related sub-acute chronic inflammation has been associated with incident type 2 diabetes and atherosclerotic cardiovascular disease. Inflammation is increasingly considered to be a pathologic mediator of these commonly co-occurring diseases.
Why this rating
Strong preclinical and epidemiologic data; clinical trials are ongoing or show mixed results for specific interventions.
Source
Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk
Allison B. Goldfine et al. · Journal of Clinical Investigation · 2017
DOI 10.1172/jci88884
More from this paper
- Statins reduce cardiovascular events and inflammatory markers (CRP) but may increase the risk of new-onset diabetes, indicating a trade-off between cardiovascular protection and glycemic control.Strong
- IL-1β antagonists (e.g., anakinra, gevokizumab) improve glycemia and beta-cell function in type 2 diabetes, but their effect on cardiovascular events is still being determined in large trials.Moderate
- Salsalate, a non-acetylated salicylate, lowers blood glucose and triglycerides in type 2 diabetes by activating AMPK and inhibiting NF-κB, but its effect on cardiovascular plaque progression is unclear.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →